Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 3/20 | 1.00 |
| ▸ | TOP2B | Q02880 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Icrf-193 SCHEMBL438498 | 1.00 | TOP2A (1.00) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| Icrf-193 SCHEMBL14006976 | 1.00 | TOP2A (1.00) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| Icrf-193 SCHEMBL27318121 | 1.00 | TOP2A (1.00) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL18618027 | 0.87 | TOP2A (0.76) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL728997 | 0.84 | TOP2A (0.73) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL13857354 | 0.84 | TOP2A (0.73) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL19505555 | 0.84 | TOP2A (1.00) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL727291 | 0.81 | TOP2A (0.67) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| Icrf-193 SCHEMBL9752440 | 0.81 | TOP2A (0.66) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL14006912 | 0.80 | TOP2A (0.65) | TOP2ATOP2BALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12070470-B2 | Topoisomerase inhibitor for mimicking the effect of ionizing radiations on T cells | NOVAGRAY (FR) | 2024-08-27 | — | — | US | claimed |
| EP-3801622-B1 | A TOPOISOMERASE INHIBITOR FOR MIMICKING THE EFFECT OF IONIZING RADIATIONS ON T CELLS | NOVAGRAY (FR) | 2022-08-31 | — | — | EP | claimed |
| US-20130171105-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2013-07-04 | — | — | US | claimed |
| EP-2575810-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR | Synta Pharmaceuticals Corp. (US) | 2013-04-10 | — | — | EP | claimed |
| WO-2011149824-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2011-12-01 | — | — | WO | claimed |
| JP-2011524851-A | — | — | 2011-09-08 | — | — | JP | claimed |
| EP-2242360-A2 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | Tosk, Inc. (US) | 2010-10-27 | — | — | EP | claimed |
| WO-2009102808-A2 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOSK, INCORPORATED (US) | 2009-08-20 | — | — | WO | claimed |
| EP-4739713-A1 | ANTI-TROP2 ANTIBODIES | Agency for Science, Technology and Research (SG) | 2026-05-13 | — | — | EP | disclosed |
| US-20260125709-A1 | METHOD FOR TARGETED ALTERATION OF DUPLEX DNA | KEYGENE N.V. (NL) | 2026-05-07 | — | — | US | disclosed |
| EP-3226909-B1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12597519-B2 | Methods for characterizing and treating a cancer type using cancer images | TESARO, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-12584140-B2 | Type V CRISPR/nuclease-system for genome editing in plant cells | KEYGENE N.V. (NL) | 2026-03-24 | — | — | US | disclosed |
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-03 | — | — | US | disclosed |
| EP-2242360-A2 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | Tosk, Inc. (US) | 2010-10-27 | — | — | EP | disclosed |
| US-20090325893-A1 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOSK, INCORPORATED | 2009-12-31 | — | — | US | disclosed |
| WO-2009102808-A2 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOSK, INCORPORATED (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-1991000729-A2 | BIS-DIOXOPIPERAZINES, AND THEIR USE AS PROTECTING AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1991-01-24 | — | — | WO | disclosed |
| EP-0409499-A2 | Pharmaceutical compositions | BTG INTERNATIONAL LIMITED (GB) | 1991-01-23 | — | — | EP | disclosed |
| US-4275063-A | 1,2-BIS(3,5-DIOXOPIPERAZIN-YL)PROPANE FOR TREATMENT OF CANCER IN HUMANS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1981-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125709-A1 | METHOD FOR TARGETED ALTERATION OF DUPLEX DNA | CPSF1, CPSF6, POF1B | TOP2A 2745/4885TOP2B 3399/4885ALDH1A1 4828/4885 |
| US-20130171105-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR | TOP2A, HSP90AB1, HSP90AB2P | TOP2A 1/4885TOP2B 5/4885ALDH1A1 3203/4885 |
| US-12584140-B2 | Type V CRISPR/nuclease-system for genome editing in plant cells | AMPD2, ENDOD1, AMPD1 | TOP2A 1941/4885TOP2B 2621/4885ALDH1A1 3080/4885 |
| US-20090325893-A1 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOP2A, TLR5, MYD88 | TOP2A 1/4885TOP2B 5/4885ALDH1A1 2086/4885 |
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | RIPK1, RIPK4, RIPK2 | TOP2A 3160/4885TOP2B 3890/4885ALDH1A1 4643/4885 |
| US-12597519-B2 | Methods for characterizing and treating a cancer type using cancer images | BRCA1, RAD51, RAD54L | TOP2A 79/4885TOP2B 94/4885ALDH1A1 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.